(3R)-4-[dimethyl(trideuteriomethyl)azaniumyl]-3-tetradecanoyloxybutanoate:hydrochloride

Myristoyl-L-carnitine-d₃ is intended for use as an internal standard for the quantification of myristoyl-L-carnitine by GC- or LC-MS. Myristoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Plasma levels of myristoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.

Myristoyl-L-carnitine-d3 Hydrochloride is labelled Myristoyl-L-carnitine Hydrochloride (M884745), a long-chain fatty ester of carnitine which is accumulated and released into the circulation, in fatty-acid oxidation defects. Pattern of Lauroyl-L-carnitine can be diagnostic for a number of -oxidation defects.

[1] STEPHANIE E REUTER. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease.[J]. Annals of Clinical Biochemistry, 2005, 42 Pt 5: 387-393. DOI: 10.1258/0004563054889954
[2] S. E. REUTER  A. M E. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity[J]. Journal of Internal Medicine, 2010, 270 1: 76-84. DOI: 10.1111/j.1365-2796.2010.02341.x